Abstract:Health care systems have benefitted from rational drug discovery processes like vHTS, virtual high throughput screening pharmacophores and quantitative structure-activity relationships, and many challenges have been explored using such techniques: decisions on specificity and selectivity are made after screening millions of molecules for multiple targets. Recent challenges in drug research emphasize the design of drugs that bind with more than one target of interest (multi-target) and do not bind with undesirable targets. This work attempts to use a three-dimensional interaction profile of the active site of a class of proteins, identify selective positions for the binding of functional groups, called features, and develop ensembles of multi-targeted pharmacophores that retain specificity and selectivity. The goal of this study is to develop multi-target pharmacophores by computational methods using protein structures alone to guide the discovery of novel inhibitors of plasmepsins, displaying selectivity over their human homologs, cathepsin D and pepsin. The development of such novel tools is attempted using a combination of different approaches such as the molecular interaction field, clique graph and inductive logic programming to identify and compare specific and selective complementary features. The identification of selective combinations of features has resulted in the design of multi-featured specific and selective pharmacophores that are validated using antimalarial compounds in ChEMBL that are known for their anti-plasmepsin II activity. This novel method is computationally less intensive and is applicable to any known class of target structures for finding specific and selective binders simultaneously.

Molecular hybridization: a powerful tool for multitarget drug discovery

Discovery of multitarget inhibitors by combining molecular docking with common pharmacophore matching.

In-Silico Approaches to Multi-target Drug Discovery

Molecular Hybridization as a Tool in the Design of Multi-target Directed Drug Candidates for Neurodegenerative Diseases

Targeted Molecular Diversity in Drug Discovery: Integration of Structure-Based Design and Combinatorial Chemistry

Computational Multitarget Drug Design.

Computer Aided Multi-target Drug Design, Multi-target Virtual Screening

Application Advances on Novel Techniques in Multi-target Drugs Discovery

How to design multi-target drugs: Target search options in cellular networks

Molecular Docking and Structure-Based Drug Design Strategies

Recent Advances in the Rational Drug Design Based on Multi-target Ligands.

Recent Advances In The Rational Drug Design Based On Multi-Target Ligands

Proteomic methods for drug target discovery

Recent advances in multitarget-directed ligands via in silico drug discovery

Molecular Docking: Shifting Paradigms in Drug Discovery

A Novel Strategy for Designing the Magic Shotguns for Distantly Related Target Pairs

[Multi-Target Therapeutics and New Drug Discovery].

Hit me with your best shot: Integrated hit discovery for the next generation of drug targets

Multiple target-based pharmacophore design from active site structures

Design of Multitarget Ligands with an Iterative Fragment-Growing Strategy.